MetaCap

Replimune Group Earnings

NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

19.07-0.16 (-0.83%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Replimune Group earnings summary

In its most recent report on Oct 28, 2026 (Sep/2026), REPL posted EPS of $-0.54 versus the $-0.70 consensus estimate, a positive surprise of 22.9%. Across the last 16 reports, REPL shares moved an average of 7.8% (in either direction) in the first trading session after results, rising 8 times and falling 8 times.

Summary generated from market data by MetaCap's automated system. Methodology

REPL earnings history

Replimune Group reported EPS versus estimates
Report dateEPS est.EPS actualSurprisePrice reaction
Oct 28, 2026$-0.70$-0.54+22.9%+22.8%
Aug 14, 2026—$-0.72—-1.3%
Jun 29, 2026—$-0.76—-5.1%
Feb 3, 2026—$-0.77—+2.8%
Nov 6, 2025—$-0.90—+8.2%
Aug 7, 2025—$-0.95—+5.1%
May 22, 2025—$-0.82—+7.5%
Feb 12, 2025—$-0.79—-0.9%
Nov 12, 2024—$-0.68—+38.2%
Aug 8, 2024—$-0.78—+5.5%
May 16, 2024—$-0.82—-18.9%
Feb 8, 2024—$-0.77—-0.4%
Nov 7, 2023—$-0.90—-6.4%
Aug 3, 2023—$-0.75—+0.8%
May 18, 2023—$-0.73—-0.5%
Feb 9, 2023—$-0.69—-0.4%

Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.

Related